Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Ponatinib use in two pediatric patients with relapsed Ph + ALL with ABL1 kinase domain mutations.

Gruner SE, Sayeed H, Suarez-Ferguson L, Perez C, Rouce R, Fisher KE, Rau RE.

Pediatr Hematol Oncol. 2019 Sep 11:1-6. doi: 10.1080/08880018.2019.1656685. [Epub ahead of print] No abstract available.

PMID:
31510844
2.

Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.

Hashmi SK, Punia JN, Marcogliese AN, Gaikwad AS, Fisher KE, Roy A, Rao P, Lopez-Terrada DH, Ringrose J, Loh ML, Niemeyer CM, Rau RE.

Pediatr Blood Cancer. 2019 Oct;66(10):e27905. doi: 10.1002/pbc.27905. Epub 2019 Jun 28.

PMID:
31250550
3.

Genetic characterization of medullary thyroid cancer in childhood survivors of the Chernobyl accident.

Fisher SB, Cote GJ, Bui-Griffith JH, Lu W, Tang X, Hai T, Fisher KE, Williams MD, Wistuba II, Waguespack SG, Dorman CM, Ludwig MS, Graham PH, Perrier ND, Lee JE, Grubbs EG.

Surgery. 2019 Jan;165(1):58-63. doi: 10.1016/j.surg.2018.08.029. Epub 2018 Nov 2.

PMID:
30392857
4.

Multimodal molecular analysis of an atypical small cell carcinoma of the ovary, hypercalcemic type.

David MP, Venkatramani R, Lopez-Terrada DH, Roy A, Patil N, Fisher KE.

Cold Spring Harb Mol Case Stud. 2018 Oct 1;4(5). pii: a002956. doi: 10.1101/mcs.a002956. Print 2018 Oct.

5.

Hyphal tip growth and cytoplasmic characters of Conidiobolus coronatus (Zoopagomycota, Entomophthoromycotina).

Fisher KE, Romberger I, Lowry D, Shange P, Roberson RW.

Mycologia. 2018 Jan-Feb;110(1):31-38. doi: 10.1080/00275514.2017.1403808.

PMID:
29864001
6.

Somatic mutations in children with GATA2-associated myelodysplastic syndrome who lack other features of GATA2 deficiency.

Fisher KE, Hsu AP, Williams CL, Sayeed H, Merritt BY, Elghetany MT, Holland SM, Bertuch AA, Gramatges MM.

Blood Adv. 2017 Feb 27;1(7):443-448. doi: 10.1182/bloodadvances.2016002311. eCollection 2017 Feb 28.

7.

A Rare Case of Pediatric Chronic Myelogenous Leukemia Presenting With Severe Thrombocytosis Without Leukocytosis.

Huho AN, Issaq N, Iacobas I, Elghetany TM, López-Terrada D, Fisher KE, Punia JN.

Pediatr Dev Pathol. 2018 Jan-Feb;21(1):100-104. doi: 10.1177/1093526617698601. Epub 2017 Mar 20.

PMID:
29187020
8.

Bioinformatics Education in Pathology Training: Current Scope and Future Direction.

Clay MR, Fisher KE.

Cancer Inform. 2017 Apr 10;16:1176935117703389. doi: 10.1177/1176935117703389. eCollection 2017. Review.

9.

Survivorship of Z-Pheromone Race European Corn Borer (Lepidoptera: Crambidae) on a Range of Host Plants Varying in Defensive Chemistry.

Fisher KE, Mason CE, Flexner JL, Hough-Goldstein J, McDonald JH.

J Econ Entomol. 2017 Jun 1;110(3):978-985. doi: 10.1093/jee/tox066.

PMID:
28334330
10.

The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis.

Ballester LY, Cantu MD, Lim KPH, Sarabia SF, Ferguson LS, Renee Webb C, Allen CE, McClain KL, Mohila CA, Punia JN, Roy A, López-Terrada DH, John Hicks M, Fisher KE.

Hematol Oncol. 2018 Feb;36(1):307-315. doi: 10.1002/hon.2388. Epub 2017 Feb 20.

PMID:
28219109
11.

Hyphal tip cytoplasmic organization in four zygomycetous fungi.

Fisher KE, Roberson RW.

Mycologia. 2016 May-Jun;108(3):533-42. doi: 10.3852/15-226. Epub 2016 Feb 23.

PMID:
26908648
12.

Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.

Fisher KE, Zhang L, Wang J, Smith GH, Newman S, Schneider TM, Pillai RN, Kudchadkar RR, Owonikoko TK, Ramalingam SS, Lawson DH, Delman KA, El-Rayes BF, Wilson MM, Sullivan HC, Morrison AS, Balci S, Adsay NV, Gal AA, Sica GL, Saxe DF, Mann KP, Hill CE, Khuri FR, Rossi MR.

J Mol Diagn. 2016 Mar;18(2):299-315. doi: 10.1016/j.jmoldx.2015.11.006. Epub 2016 Jan 20.

13.

Clinical Significance of Positive Pelvic Washings in Uterine Papillary Serous Carcinoma Confined to an Endometrial Polyp.

Hanley KZ, Fadare O, Fisher KE, Atkins KA, Mosunjac MB.

Int J Gynecol Pathol. 2016 May;35(3):249-55. doi: 10.1097/PGP.0000000000000235.

PMID:
26535985
14.

Development and validation of CALR mutation testing for clinical diagnosis.

Maier CL, Fisher KE, Jones HH, Hill CE, Mann KP, Zhang L.

Am J Clin Pathol. 2015 Nov;144(5):738-45. doi: 10.1309/AJCPXPA83MVCTSOQ.

PMID:
26486738
15.

BRAF p.V600E immunohistochemistry in challenging samples: about false-positive and false-negative results--reply.

Fisher KE, Cohen C, Palma JF, Longshore JW.

Hum Pathol. 2015 Jul;46(7):1065-6. doi: 10.1016/j.humpath.2015.03.011. Epub 2015 Apr 11. No abstract available.

PMID:
25971545
16.

Section IV: non-small cell lung cancer and malignant melanoma.

Fisher KE, Pillai RN, Kudchadkar RR, Rossi MR.

Curr Probl Cancer. 2014 Sep-Oct;38(5):180-98. doi: 10.1016/j.currproblcancer.2014.08.007. Epub 2014 Aug 14. Review. No abstract available.

PMID:
25281457
17.

The role of immunohistochemical analysis in the evaluation of EML4-ALK gene rearrangement in lung cancer.

Sullivan HC, Fisher KE, Hoffa AL, Wang J, Saxe D, Siddiqui MT, Cohen C.

Appl Immunohistochem Mol Morphol. 2015 Apr;23(4):239-44. doi: 10.1097/PAI.0000000000000088.

PMID:
25265433
18.

Section III: molecular diagnostics in neuro-oncology.

Neill SG, Fisher KE.

Curr Probl Cancer. 2014 Sep-Oct;38(5):175-9. doi: 10.1016/j.currproblcancer.2014.08.006. Epub 2014 Aug 14. Review. No abstract available.

PMID:
25263767
19.

Section I: integrating laboratory medicine with tissue specimens.

Fisher KE, Smith GH, Neill SG, Rossi MR.

Curr Probl Cancer. 2014 Sep-Oct;38(5):144-58. doi: 10.1016/j.currproblcancer.2014.08.004. Epub 2014 Aug 14. No abstract available.

PMID:
25239562
20.

Section II: hematolymphoid malignancies.

Zhang L, Rossi MR, Fisher KE.

Curr Probl Cancer. 2014 Sep-Oct;38(5):159-74. doi: 10.1016/j.currproblcancer.2014.08.005. Epub 2014 Aug 14. Review. No abstract available.

PMID:
25239561
21.

Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.

Fisher KE, Cohen C, Siddiqui MT, Palma JF, Lipford EH 3rd, Longshore JW.

Hum Pathol. 2014 Nov;45(11):2281-93. doi: 10.1016/j.humpath.2014.07.014. Epub 2014 Aug 7.

PMID:
25228337
22.

Introduction: molecular genomics of cancer: linking diagnostic testing and clinical therapy.

Fisher KE, Neill SG, Smith GH, Pillai RN, Kudchadkar RR, Zhang L, Rossi MR.

Curr Probl Cancer. 2014 Sep-Oct;38(5):142-3. doi: 10.1016/j.currproblcancer.2014.08.003. Epub 2014 Aug 14. No abstract available.

PMID:
25220586
23.

BRAF mutations in metastatic malignant melanoma: comparison of molecular analysis and immunohistochemical expression.

Ehsani L, Cohen C, Fisher KE, Siddiqui MT.

Appl Immunohistochem Mol Morphol. 2014 Oct;22(9):648-51. doi: 10.1097/PAI.0000000000000013.

PMID:
25046227
24.

Immunohistochemical Investigation of BRAF p.V600E mutations in thyroid carcinoma using 2 separate BRAF antibodies.

Fisher KE, Neill SG, Ehsani L, Caltharp SA, Siddiqui MT, Cohen C.

Appl Immunohistochem Mol Morphol. 2014 Sep;22(8):562-7. doi: 10.1097/PAI.0b013e3182a2f75f.

PMID:
24897065
25.

HER2 in resected gastric cancer: Is there prognostic value?

Fisher SB, Fisher KE, Squires MH 3rd, Patel SH, Kooby DA, El-Rayes BF, Cardona K, Russell MC, Staley CA 3rd, Farris AB 3rd, Maithel SK.

J Surg Oncol. 2014 Feb;109(2):61-6. doi: 10.1002/jso.23456. Epub 2013 Oct 10.

PMID:
24122802
26.

The General Surgeon's quandary: atypical lipomatous tumor vs lipoma, who needs a surgical oncologist?

Fisher SB, Baxter KJ, Staley CA 3rd, Fisher KE, Monson DK, Murray DR, Oskouei SV, Weiss SW, Kooby DA, Maithel SK, Delman KA.

J Am Coll Surg. 2013 Nov;217(5):881-8. doi: 10.1016/j.jamcollsurg.2013.06.003. Epub 2013 Sep 25.

27.

Gene expression profiling of clear cell papillary renal cell carcinoma: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.

Fisher KE, Yin-Goen Q, Alexis D, Sirintrapun JS, Harrison W, Benjamin Isett R, Rossi MR, Moreno CS, Young AN, Osunkoya AO.

Mod Pathol. 2014 Feb;27(2):222-30. doi: 10.1038/modpathol.2013.140. Epub 2013 Jul 26.

28.

Costs of a contact screening activity in a neonatal intensive care unit.

Fisher KE, Cook NF, Marks GB.

N S W Public Health Bull. 2013 Jul;24(1):29-31. doi: 10.1071/NB12108. No abstract available.

29.

Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.

Fisher KE, Jani JC, Fisher SB, Foulks C, Hill CE, Weber CJ, Cohen C, Sharma J.

J Surg Res. 2013 Nov;185(1):217-24. doi: 10.1016/j.jss.2013.05.003. Epub 2013 May 23.

30.

Nosocomial pulmonary tuberculosis contact investigation in a neonatal intensive care unit.

Fisher KE, Guaran R, Stack J, Simpson S, Krause W, For KD, Ryan E, Conaty S, Hope K, Isaacs D, Chay P, Eastwood J, Marks GB.

Infect Control Hosp Epidemiol. 2013 Jul;34(7):754-6. doi: 10.1086/670995. Epub 2013 May 22.

PMID:
23739083
31.

Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma.

Squires MH 3rd, Fisher SB, Fisher KE, Patel SH, Kooby DA, El-Rayes BF, Staley CA 3rd, Farris AB 3rd, Maithel SK.

Cancer. 2013 Sep 1;119(17):3242-50. doi: 10.1002/cncr.28175. Epub 2013 May 29.

32.

Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.

Isham CR, Bossou AR, Negron V, Fisher KE, Kumar R, Marlow L, Lingle WL, Smallridge RC, Sherman EJ, Suman VJ, Copland JA, Bible KC.

Sci Transl Med. 2013 Jan 2;5(166):166ra3. doi: 10.1126/scitranslmed.3004358.

33.

Molecular targeted therapy for biliary tract malignancy: defining the target.

Fisher SB, Fisher KE, Maithel SK.

Hepatobiliary Surg Nutr. 2012 Dec;1(1):53-4. doi: 10.3978/j.issn.2304-3881.2012.10.02. No abstract available.

34.

Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease.

Brodney MA, Johnson DE, Sawant-Basak A, Coffman KJ, Drummond EM, Hudson EL, Fisher KE, Noguchi H, Waizumi N, McDowell LL, Papanikolaou A, Pettersen BA, Schmidt AW, Tseng E, Stutzman-Engwall K, Rubitski DM, Vanase-Frawley MA, Grimwood S.

J Med Chem. 2012 Nov 8;55(21):9240-54. doi: 10.1021/jm300953p. Epub 2012 Oct 5.

PMID:
22974325
35.

Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.

Fisher SB, Fisher KE, Patel SH, Lim MG, Kooby DA, El-Rayes BF, Staley CA 3rd, Adsay NV, Farris AB 3rd, Maithel SK.

Cancer. 2013 Jan 15;119(2):454-62. doi: 10.1002/cncr.27739. Epub 2012 Jul 3.

36.

The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal θ oscillations.

Johnson DE, Drummond E, Grimwood S, Sawant-Basak A, Miller E, Tseng E, McDowell LL, Vanase-Frawley MA, Fisher KE, Rubitski DM, Stutzman-Engwall KJ, Nelson RT, Horner WE, Gorczyca RR, Hajos M, Siok CJ.

J Pharmacol Exp Ther. 2012 Jun;341(3):681-91. doi: 10.1124/jpet.112.192351. Epub 2012 Mar 9.

PMID:
22408061
37.

Biochemical characterization of human HIF hydroxylases using HIF protein substrates that contain all three hydroxylation sites.

Pappalardi MB, McNulty DE, Martin JD, Fisher KE, Jiang Y, Burns MC, Zhao H, Ho T, Sweitzer S, Schwartz B, Annan RS, Copeland RA, Tummino PJ, Luo L.

Biochem J. 2011 Jun 1;436(2):363-9. doi: 10.1042/BJ20101201.

PMID:
21410436
38.

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.

Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang J, Zappacosta F, Annan R, Sutton D, Laquerre SG.

Clin Cancer Res. 2011 Mar 1;17(5):989-1000. doi: 10.1158/1078-0432.CCR-10-2200. Epub 2011 Jan 18. Erratum in: Clin Cancer Res. 2012 Apr 15;18(8):2413.

39.

Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.

Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH, Fisher KE, Hamajima T, Hardwicke MA, Huffman WF, Koretke-Brown KK, Lai ZV, McDonald OB, Nakamura H, Newlander KA, Oleykowski CA, Parrish CA, Patrick DR, Plant R, Sarpong MA, Sasaki K, Schmidt SJ, Silva DJ, Sutton D, Tang J, Thompson CS, Tummino PJ, Wang JC, Xiang H, Yang J, Dhanak D.

J Med Chem. 2010 May 27;53(10):3973-4001. doi: 10.1021/jm901870q.

PMID:
20420387
40.

Endothelial lumen signaling complexes control 3D matrix-specific tubulogenesis through interdependent Cdc42- and MT1-MMP-mediated events.

Sacharidou A, Koh W, Stratman AN, Mayo AM, Fisher KE, Davis GE.

Blood. 2010 Jun 24;115(25):5259-69. doi: 10.1182/blood-2009-11-252692. Epub 2010 Mar 9.

41.

MT1-MMP- and Cdc42-dependent signaling co-regulate cell invasion and tunnel formation in 3D collagen matrices.

Fisher KE, Sacharidou A, Stratman AN, Mayo AM, Fisher SB, Mahan RD, Davis MJ, Davis GE.

J Cell Sci. 2009 Dec 15;122(Pt 24):4558-69. doi: 10.1242/jcs.050724. Epub 2009 Nov 24.

42.

3D timelapse analysis of muscle satellite cell motility.

Siegel AL, Atchison K, Fisher KE, Davis GE, Cornelison DD.

Stem Cells. 2009 Oct;27(10):2527-38. doi: 10.1002/stem.178.

43.

Endothelial cell lumen and vascular guidance tunnel formation requires MT1-MMP-dependent proteolysis in 3-dimensional collagen matrices.

Stratman AN, Saunders WB, Sacharidou A, Koh W, Fisher KE, Zawieja DC, Davis MJ, Davis GE.

Blood. 2009 Jul 9;114(2):237-47. doi: 10.1182/blood-2008-12-196451. Epub 2009 Apr 1.

44.

Lay information mediary behavior uncovered: exploring how nonprofessionals seek health information for themselves and others online.

Abrahamson JA, Fisher KE, Turner AG, Durrance JC, Turner TC.

J Med Libr Assoc. 2008 Oct;96(4):310-23. doi: 10.3163/1536-5050.96.4.006.

45.

Engineering substrate preference in subtilisin: structural and kinetic analysis of a specificity mutant.

Ruan B, London V, Fisher KE, Gallagher DT, Bryan PN.

Biochemistry. 2008 Jun 24;47(25):6628-36. doi: 10.1021/bi800089f.

PMID:
18507395
46.

Main chain NMR assignments of subtilisin Sbt70 in its prodomain-bound state.

Sari N, Fisher KE, Bryan PN, Orban J.

Biomol NMR Assign. 2007 Dec;1(2):209-11. doi: 10.1007/s12104-007-9058-4. Epub 2007 Nov 1.

PMID:
19636867
47.

Hydrogen-deuterium exchange in free and prodomain-complexed subtilisin.

Sari N, Ruan B, Fisher KE, Alexander PA, Orban J, Bryan PN.

Biochemistry. 2007 Jan 23;46(3):652-8.

PMID:
17223687
48.

Mechanism of the kinetically-controlled folding reaction of subtilisin.

Fisher KE, Ruan B, Alexander PA, Wang L, Bryan PN.

Biochemistry. 2007 Jan 23;46(3):640-51.

PMID:
17223686
50.

Directed coevolution of stability and catalytic activity in calcium-free subtilisin.

Strausberg SL, Ruan B, Fisher KE, Alexander PA, Bryan PN.

Biochemistry. 2005 Mar 8;44(9):3272-9.

PMID:
15736937

Supplemental Content

Loading ...
Support Center